Technical Analysis for SYRS - Syros Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 12.07 -3.05% -0.38
SYRS closed down 3.05 percent on Thursday, July 19, 2018, on 66 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Earnings due: Aug 8

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical SYRS trend table...

Date Alert Name Type % Chg
Jul 19 Downside 200 DMA Break Bearish 0.00%
Jul 19 Fell Below 50 DMA Bearish 0.00%
Jul 19 Wide Bands Range Expansion 0.00%
Jul 19 Overbought Stochastic Strength 0.00%
Jul 19 Down 3 Days in a Row Weakness 0.00%
Jul 18 Bearish Engulfing Bearish -3.05%
Jul 18 Stochastic Sell Signal Bearish -3.05%
Jul 18 200 DMA Support Bullish -3.05%
Jul 18 50 DMA Support Bullish -3.05%
Jul 18 Wide Bands Range Expansion -3.05%

Older signals for SYRS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Is SYRS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 24.38
52 Week Low 6.3
Average Volume 220,458
200-Day Moving Average 12.2236
50-Day Moving Average 12.1638
20-Day Moving Average 11.472
10-Day Moving Average 12.259
Average True Range 0.6049
ADX 21.66
+DI 26.7844
-DI 19.4331
Chandelier Exit (Long, 3 ATRs ) 11.4453
Chandelier Exit (Short, 3 ATRs ) 11.8847
Upper Bollinger Band 13.2013
Lower Bollinger Band 9.7427
Percent B (%b) 0.67
BandWidth 30.148187
MACD Line 0.1098
MACD Signal Line -0.043
MACD Histogram 0.1528
Fundamentals Value
Market Cap 316.96 Million
Num Shares 26.3 Million
EPS -2.11
Price-to-Earnings (P/E) Ratio -5.72
Price-to-Sales 289.82
Price-to-Book 4.51
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.84
Resistance 3 (R3) 12.86 12.62 12.71
Resistance 2 (R2) 12.62 12.43 12.61 12.66
Resistance 1 (R1) 12.35 12.31 12.23 12.33 12.62
Pivot Point 12.11 12.11 12.06 12.10 12.11
Support 1 (S1) 11.84 11.92 11.72 11.82 11.52
Support 2 (S2) 11.60 11.80 11.59 11.48
Support 3 (S3) 11.33 11.60 11.43
Support 4 (S4) 11.31